| Jason G Wilmoth, MD | |
|
1245 Highland Ave, Suite 502, Abington, PA 19001-3714 | |
| (215) 886-1482 | |
| (215) 886-1491 |
| Full Name | Jason G Wilmoth |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 28 Years |
| Location | 1245 Highland Ave, Abington, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326080185 | NPI | - | NPPES |
| 0018922340001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD073797L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abington Memorial Hospital | Abington, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Methodist Associates In Healthcare, Inc | 6406755651 | 264 |
News Archive
Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.
Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival.
Researchers at the University of Colorado Anschutz Medical Campus, along with seven other major institutions, have found that even mild postoperative pulmonary complications (PPCs) are significantly associated with increased death within the first week after surgery.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 5 days ago
| Entity Name | Methodist Associates In Healthcare, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053355131 PECOS PAC ID: 6406755651 Enrollment ID: O20040402000835 |
News Archive
Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.
Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival.
Researchers at the University of Colorado Anschutz Medical Campus, along with seven other major institutions, have found that even mild postoperative pulmonary complications (PPCs) are significantly associated with increased death within the first week after surgery.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 5 days ago
| Entity Name | Pinnacle Ent Alliance Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538230313 PECOS PAC ID: 7416963988 Enrollment ID: O20060222000064 |
News Archive
Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.
Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival.
Researchers at the University of Colorado Anschutz Medical Campus, along with seven other major institutions, have found that even mild postoperative pulmonary complications (PPCs) are significantly associated with increased death within the first week after surgery.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 5 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275858920 PECOS PAC ID: 3274437736 Enrollment ID: O20100628001035 |
News Archive
Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.
Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival.
Researchers at the University of Colorado Anschutz Medical Campus, along with seven other major institutions, have found that even mild postoperative pulmonary complications (PPCs) are significantly associated with increased death within the first week after surgery.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason G Wilmoth, MD 994 Old Eagle School Rd, Suite 1017, Wayne, PA 19087-1802 Ph: (610) 902-6092 | Jason G Wilmoth, MD 1245 Highland Ave, Suite 502, Abington, PA 19001-3714 Ph: (215) 886-1482 |
News Archive
Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.
Moffitt Cancer Center researchers discovered that patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival.
Researchers at the University of Colorado Anschutz Medical Campus, along with seven other major institutions, have found that even mild postoperative pulmonary complications (PPCs) are significantly associated with increased death within the first week after surgery.
Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH Abstract # 1033).
› Verified 5 days ago
Kenneth H Einhorn, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1245 Highland Ave, Suite 502, Abington, PA 19001 Phone: 215-886-1482 Fax: 215-886-1491 | |
Philip A Rosenfeld, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1245 Highland Ave, Suite 502, Abington, PA 19001 Phone: 215-886-1482 Fax: 215-886-1491 |